MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

531.8 1.44

Buy Sell

Overview

Share price change

24h

Current

Min

524.96

Max

531.8

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+27.25% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.5B 12B
Previous open	530.36
Previous close	531.8

News Sentiment

By Acuity

50%

135 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 kwi 2026, 23:48 UTC

Major News Events

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19 kwi 2026, 23:36 UTC

Major News Events

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19 kwi 2026, 22:47 UTC

Major News Events

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19 kwi 2026, 23:49 UTC

Market Talk

Major News Events

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19 kwi 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19 kwi 2026, 23:38 UTC

Major News Events

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19 kwi 2026, 23:12 UTC

Major News Events

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19 kwi 2026, 23:10 UTC

Major News Events

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19 kwi 2026, 23:09 UTC

Major News Events

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19 kwi 2026, 23:08 UTC

Major News Events

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18 kwi 2026, 01:00 UTC

Major News Events

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 kwi 2026, 22:58 UTC

Earnings

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 kwi 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 kwi 2026, 20:52 UTC

Earnings

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 kwi 2026, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 kwi 2026, 20:29 UTC

Earnings

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

27.25% upside

12 Months Forecast

Average 677 USD 27.25%

High 964 USD

Low 529 USD

Based on 8 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

135 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.